High prevalence of neurocognitive disorders observed among adult people living with HIV/AIDS in Southern Ethiopia: a cross-sectional study.

debalkie, m.; Bekele, M.; Workineh, Y.; yihune, M.

doi:10.1101/416362

Home/Archive/bioRxiv

bioRxiv · 10.1101/416362

High prevalence of neurocognitive disorders observed among adult people living with HIV/AIDS in Southern Ethiopia: a cross-sectional study.

debalkie, m.·Bekele, M.·Workineh, Y.·yihune, M.

View original source ↗Export metadata ↓

Abstract

BackgroundComprehensive care given to people living with HIV/AIDS is improving from time to time; however, their concurrent cognitive illness is still ignored, under screened and treated particularly in developing countries. And this problem is also striking in Ethiopia. Therefore, the objective of this study was to assess HIV-associated neurocognitive disorders and associated factors among adult people living with HIV/AIDS.\n\nMethodsAn institution based cross sectional study was conducted in Gamo Gofa zone public Hospitals from April to May, 2017. The systematic random sampling technique was used to select a total of 697 people living with HIV/AIDS. Data was collected using structured interviewer administered questionnaire and International HIV Dementia Scale was used to screen HIV-associated neurocognitive deficits. Data was entered using Epidata version 3.1 and analyzed using SPSS version 20. Both bivariable and multivariable logistic regression analyses were performed to identify associated factors. A P value 0.05 with 95% confidence level was used to declare statistical significance.\n\nResultA total of 684 study participants were included with a 98 % response rate. From the total participants, 56% were females while 44% were males. The mean ({+/-}SD) age of the participants was 38.8{+/-}8.8years.\n\nThe prevalence of HIV-associated neurocognitive disorder was 67.1% (95%CI; 63.6, 70.5). The multivariable logistic analysis indicated that body mass index 16 kg/m2 (AOR 4.149 (1.512-11.387)), being married (AOR 0.9 (0.604-0.623), unemployment (AOR 5.930 (3.013-11.670) and being in WHO clinical stage T3 category (AOR 2.870 (1.098-7.500) were the key predictors of HIV-associated neurocognitive disorders among people living with HIV/AIDS.\n\nConclusionIn this study the prevalence of HIV-associated neurocognitive disorder is higher than the earlier reports in Ethiopia and Africa. The associated factors also vary from that of earlier studies. This indicates the need for formulating preventive mental health programs and policies for people living with HIV/AIDS.

Source connections

Published article ↗

Explore related subjects

neuroscience Preprint

Keep this discovery

BibTeX RIS

debalkie, m., Bekele, M., Workineh, Y., yihune, M.. 2018-09-13. High prevalence of neurocognitive disorders observed among adult people living with HIV/AIDS in Southern Ethiopia: a cross-sectional study.. https://doi.org/10.1101/416362

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

The Unreasonable Effectiveness of Cell Types in Describing Neuronal Physiological Features

Single-cell RNA sequencing (scRNA-seq) captures detailed gene expression profiles at scale, while patch-clamp recordings measure intrinsic neuronal electrophysiological properties. Modeling the relations between these two modalities remains a challenge. Here, we compare how well electrophysiological features can be predicted by traditional transcriptomic cell type classification, representations derived from a foundational model (scGPT) pretrained on large-scale scRNA-seq datasets, ion channel-coding genes, and highly variable genes. Using paired transcriptomic and electrophysiological patch-sequencing data from 495 human neurons from neurosurgical tissue, we find that cluster-level cell type representations consistently outperform highly variable gene selection, ion channel gene selection, and context-enriched scGPT embeddings. Notably, performance varies across model architectures and initializations, and the best results are obtained by combining the outputs of separate cell type and scGPT-based models. Together, these findings suggest that traditional discrete cellular classification is highly effective in predicting physiological features. For maximum performance it can be complemented by pretrained transformer models.

neuroscience↗

bioRxiv2026

A nonlinear inhibition pathway underlying cortical responses to tuned holographic optogenetic perturbations

Optogenetics enables causal manipulation of cortical activity. Perturbation responses can be counterintuitive due to network interactions, making theory essential for predicting them. Existing approaches often rely on linear approximations, which fail for many biologically relevant perturbations. Here we develop a nonlinear theory of responses to holographic perturbations in cell-type-specific recurrent networks with structured connectivity. We fit a nonlinear model to mouse V1 data, which shows cotuned-ensemble suppression: perturbing spatially clustered neurons with similar preferred orientations yields markedly stronger short-range suppression than perturbing untuned ensembles. We show that cotuned-ensemble suppression arises from a feature-tuned, nonlinear inhibition pathway implicating somatostatin-positive (SST) interneurons. The theory predicts that cotuned ensembles suppress parvalbumin-positive (PV) neurons but facilitate SST neurons, and links the degree of cotuned-ensemble suppression or facilitation to the variance of the SST response. This framework identifies mechanisms by which nonlinear inhibition sculpts cortical dynamics and establishes a predictive basis for targeted optogenetic interventions.

neuroscience↗

bioRxiv2026

Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimers disease

The apolipoprotein E {varepsilon}4 (APOE {varepsilon}4) allele is the strongest genetic risk factor for late-onset Alzheimers disease (AD). However, the underlying molecular mechanisms remain unclear. This study included 1691 participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), 1226 participants from the Accelerating Medicines Partnership - Alzheimers Disease (AMP-AD) Diverse Cohorts Study, and 735 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI). To characterise APOE {varepsilon}4 molecular effects, we analysed proteomic data from plasma, cerebrospinal fluid (CSF), and induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, as well as transcriptomic and proteomic data from multiple brain regions. The association of APOE {varepsilon}4 with AD neuropathology was also examined. APOE {varepsilon}4 carriers shared a plasma proteomic signature enriched for immune processes, irrespective of AD diagnosis. A machine learning classifier trained on this signature discriminated APOE {varepsilon}4 carriers from non-carriers in an independent cohort using CSF proteomics. APOE {varepsilon}4 carriage was associated with higher Braak stages and Consortium to Establish a Registry for Alzheimers Disease (CERAD) score. However, only limited APOE {varepsilon}4-associated transcriptomic and proteomic changes were observed in bulk brain tissue, with poor cross-layer concordance. Proteomic analyses of iPSC-derived astrocytes and neurons further revealed cell-type-specific APOE {varepsilon}4-associated changes. APOE {varepsilon}4 is associated with a consistent proteomic signature across plasma and CSF. Its molecular effects in the brain differ across cell types, brain regions and molecular layers. These findings support the need for cell-type-resolved multi-omic studies to elucidate how APOE {varepsilon}4 confers AD risk.

neuroscience↗